As a trivalent vaccine targeting EphA2, HER2, and IL-13Rα2 in pediatric malignant gliomas [74] and ependymomas [75] revealed feasibility, tolerability, and efficacy pediatric brain tumors, combination of targeted antigens might be the future direction of the development of CAR T-cell therapy. This evidence concerns the gene IL13RA2 and malignant glioma.